

James Daniel Geyer

CURRICULUM VITAE

PERSONAL

Business Address Neurology Consultants of Tuscaloosa, P.C.
401 Towncenter Blvd. Suite B
Tuscaloosa, AL 35406
(205) 345-3881

ACADEMIC APPOINTMENTS

Assistant Professor Neurology and Sleep Medicine
Department of Internal Medicine
The University of Alabama, CCHS
401 Towncenter Blvd. Suite B
Tuscaloosa, AL 35406
July 1, 1998 - Present

Medical Director The Comprehensive Clinical Neurophysiology Laboratories
The DCH Sleep Laboratory
DCH Regional Medical Center
809 University Boulevard, East
Tuscaloosa, AL 35401
July 1, 1998 - Present

Attending Neurologist Neurology Consultants of Tuscaloosa, P.C.
401 Towncenter Blvd, Ste B
Tuscaloosa, AL 35406
July 1, 1998 - Present

EDUCATION

Clinical Neurophysiology
Fellowship The University of Michigan
Department of Neurology
University Hospital 1B300
Epilepsy 1500 East Medical Center Drive
Sleep Medicine Ann Arbor, MI 48109-0036
EEG 1997-1998

Neurology Residency The University of Alabama at Birmingham
Neurology Chief Resident Department of Neurology
1205 Jefferson Tower
Birmingham, AL 35249
1994-1997

Medicine Internship The University of Alabama at Birmingham
Department of Medicine

DERB 15, UAB Station
Birmingham, AL 35249
1993-1994

Medical School The University of Alabama School of Medicine
Birmingham, AL 35294
MD awarded June 1993

Undergraduate Duke University
Durham, North Carolina 27706
BSE awarded June 1987
Majors : Biomedical Engineering, Electrical Engineering

HONORS

Ortho-McNeil TOP Scholar Award 1997
Pharmacia & Upjohn Young Researcher's Award 1997
National Epi Fellows Grant 1995
S. C. Little Award for excellence in Neurology 1993
Alpha Omega Alpha 1992
Epilepsy Foundation of America Student Fellowship 1991

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Epilepsy Society (AES)
Academy of Sleep Medicine (AASM)
American Medical Association (AMA)
Medical Association of the State of Alabama (MASA)
American Society of Neuroimaging (ASN)

CERTIFICATION

Alabama Medical License
American Board of Psychiatry and Neurology 4/1998
American Board of Psychiatry and Neurology Added Qualification in Clinical Neurophysiology 1999
American Board of Sleep Medicine 2001
American Society of Neuroimaging 2002

BOOKS

“Clinical Sleep Disorders”
Eds. J. Geyer, M.D.; P. Carney, M.D.; R. Berry, M.D.
Lippincott, Williams, & Wilkins (in press)

“Neurology for the Boards”, 3rd Edition
Eds. J. Geyer MD, J. Keating MD, D. Potts MD
Lippincott Williams and Wilkins, (contract)

“Neurology for the Boards”, 2nd Edition
Eds. J. Geyer MD, J. Keating MD, D. Potts MD
Lippincott, Williams & Wilkins, 2001

“Atlas of Digital Polysomnography”
J. Geyer MD, T. Payne MD, P Carney MD, M. Aldrich MD
Lippincott-Williams-Wilkins, 2000

“Neurology for the Boards”
Eds. J. Geyer MD, J. Keating MD, D. Potts MD
Lippincott-Raven, 1998

PUBLICATIONS

“Significance of Post-ictal Nose-Rubbing in the Diagnosis, Lateralization and Localization of Seizures” J Geyer, T Payne, I Drury, RE Faught. *Neurology* 1999 march: 52 (4): 743-5.

“Rasmussen’s Encephalitis with Concomitant Cortical Dysplasia”
C. Palmer MD, J. Geyer MD, J. Keating MD, M. Bebin MD, F. Gilliam MD,
R. Kuzniecky MD, R. Morawetz MD. *Epilepsia*. February 1998 40 (2): 242-7.

“Accuracy of interictal temporal lobe delta activity for localization of the primary epileptogenic region.” J. Geyer, F. Gilliam, E. Bilir, E. Faught, R. Kuzniecky. *Neurology* (1999) Jan1: 52(1):202-5.

"Development of a Digital Signal Acquisition and Analysis System for Epilepsy Surgery"
J.D. Geyer. *Biomed Inst. Technol.* 1992 Jan-Feb: 26 (1):31-7.

"Simulation of Adaptive Control of Lidocaine Serum Concentrations Based on Sparse Measurements" T.C. Jannett and J.D. Geyer. *Biochemical Kinetics. IEEE Engineering in Medicine and Biology Society.* pp. 0262-0263, 1989.

“Informed consent, competency and the neurologist” Marson D, Dymeck M, Geyer J. *The Neurologist* Nov 2001 Vol 7 N.6 p 347-26.

“Neurodegenerative dementia: Ethical and legal issues of clinical care and research.” Marson D, Dymeck M, Geyer J. Book Chapter. In J. Trojanowski and C. Clark (eds) Neurodegenerative Dementias, New York City, N.Y.: Erlbaum. (2000)

“Delayed Iatrogenic Cerebrospinal Fistula with Complicating Meningitis” J. Geyer MD, L. Nabors MD, C. Gomez MD, L. Harrell MD *J. Neuroimaging.* 1997 Oct:7 (4):244-7.

“Non-epileptic Seizure Outcome Varies by Type of Spell and Duration of Illness.” L. Selwa MD, J. Geyer MD, N. Nikakhtar, M. Brown MA PhD, L. Schuh, MD, I. Drury MB BCh. *Epilepsia.*

“The value of pelvic thrusting in the diagnosis of seizures and pseudoseizures.” J. Geyer, M.D.; T. Payne M.D.; I. Drury, M.D. *Neurology* (January 2000) 11; 54 (1):227-9

PLATFORM PRESENTATIONS

Mortality and Hospital Utilization of Seizures in Senior Adults

J. Geyer, F. Gilliam, N. Schiesz, E. Faught, R. Kuzniecky

American Epilepsy Society

Fall 1995 Baltimore, MD

Anti-Hu Antibody Associated Paraneoplastic Vasculitic Neuropathy

J. Geyer, S. Oh, P. King, E. Dropcho

Society for Experimental Neuropathology

Fall 1995 Washington, D.C.

ABSTRACTS/POSTERS

“Discontinuation of Anticonvulsants in Nonepileptic Seizure Patients”. L. Selwa, M.D.; I. Drury, M.D.; J. Geyer, M.D.; L. Schuh, M.D.; N. Nikakhtar, M.D.; *Epilepsia* (40) supp 7 p 107, 1999.

“The Value of Pelvic Thrusting in the Diagnosis of Seizures and Pseudoseizures”. T. Payne, M.D.; J. Geyer, M.D.; I. Drury, M.D. *Epilepsia* (40) Supp 7 p110, 1999.

“Depakote and Maintenance of Weight” J. Geyer, M.D.; D. Potts, M.D. *Epilepsia* (40) supp 7, p 142, 1999.

“Rasmussen’s Encephalitis with Concomitant Cortical Dysplasia”

J. Geyer MD, J. Keating MD, C. Palmer MD, M. Bebin MD, F. Gilliam MD,

R. Kuzniecky MD, R. Morawetz MD

American Association of Neuropathologists

6/1996

“Accuracy of interictal temporal lobe delta activity for localization of the primary epileptogenic region.”

J. Geyer, F. Gilliam, E. Bilir, E. Faught, R. Kuzniecky

American Epilepsy Society

12/1996

“Transesophageal Echocardiography is Superior to Angiography in Detecting Aortic Arch Sources of Thromboembolic Ischemic Stroke”

Black M, Geyer J, Keating J, Terry J, Gomez C, Nanda N.

AAN Boston 4/1997

“Hyperchoic Middle Cerebral Artery Sign Following Acute Occlusion Detected by Transcranial Doppler Imaging.” Kadimi S, Geyer J, Terry J, Gomez C.

ANA San Diego; 10/1997

“Oncodiuretic Therapy Reduces the Development of Life-Threatening Edema Following Large Cerebral Infarction.”

Daru K, Potts D, Geyer J, Gomez C, Terry J

ANA San Diego

10/1997

“Detection of Persistent Fetal Posterior Cerebral Artery by Invasive and Non-Invasive Methods.”

Boyce S, Geyer J, Nabers M, Campbell M, Terry J, Gomez C.
ANA San Diego
10/1997

“The Effect of the Learning Curve Upon the Detection of Cardioembolic Sources of Ischemic Stroke by Transesophageal Echocardiography.”
Nabers M, Geyer J, Daru K, Terry J, Gomez C
ANA San Diego; 10/1997

“Mortality and Hospital Utilization of Seizures in Senior Adults”
J. Geyer, F. Gilliam, N. Schiesz, E. Faught, R. Kuzniecky
Epilepsia Vol. 36 Supp. 4 p.148; 1995

“Anti-Hu Antibody Associated Paraneoplastic Vasculitic Neuropathy”
J. Geyer, S. Oh, P. King, E. Dropcho
Brain Pathology; S(3): 329, 1995

CLINICAL TRIALS

Parke-Davis - “XXXXXXXXX STEPS”

RANTASS

Abbott Laboratories - “Safety and Efficacy of XXXXXXXXXXXX HCl as Adjunctive Treatment (M92-825 including administrative change #1 and #2), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Ciba-Geigy Corporation - “Safety and Efficacy of High Versus Low Dose xxxxxxxxxxxxxxxx Monotherapy in Patients with Uncontrollable Partial Onset Seizures” (47680-02-026) and Multicenter , Long-Term Extension Phase of xxxxxxxxxxxxxxxx in Patients with Uncontrolled Partial Onset Seizures (47680-02-26E), July 1997-1998 (Principal Investigator: Dr. Ahmad Beydoun)

Dainippon Pharmaceutical Company - “Long Term Safety and Efficacy Evaluation of xxxxxxxxxxxxxxxx in the Treatment of Seizures in Medically Refractory Patients and Efficacy Evaluation of Zonisamide Monotherapy” (810-921 including administrative change and amendment #1 and #2), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Dainippon Pharmaceutical Company - “Placebo Controlled Efficacy and Safety Evaluation of xxxxxxxxxxxxxxxx in the Treatment of Seizures in Medically Refractory Patients” (810-922 including amendment), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Glaxo Wellcome - “A Multicenter Continuation of the xxxxxxxxxxxxxxxx Monotherapy Studies (29 including amendment #1), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Marion Merrell Dow, Inc - “Clinical Experience and use of xxxxxx in Patients with Partial Seizures” (VGPR 0098 including amendment #1 and #2), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

R.W. Johnson Pharmaceutical Research Institute - “A Long Term, Open-Label Extension Study of xxxxxxxx” (YLT), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

R.W. Johnson Pharmaceutical Research Institute - “Multicenter xxxxxxxx Monotherapy Trial YJ”, July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

UCB SA Pharma Sector - "A Long-Term Open Label, Multicenter Study of the Safety and Efficacy of xxxxxx 500mg Tablets at Individualized Oral Doses Ranging from 1000 mg/day to 4000 mg/day in the Treatment of Epilepsy" (RPCE96A2201), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

UCB SA Pharma Sector - "A Multicenter Follow-Up Study of the Safety and Efficacy of Oral 500 mg Tablets xxxxxx in Patients with Partial Onset Epileptic Seizures: a 6-Week, Double Blind Titration to 3000 mg/day, Followed by an Open Treatment Phase at Individualized Doses" (RPCE94J1403), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Abbott laboratories - "An Open-Label Extension Study of xxxxxxxxxxx HCl in the Treatment of Patients with Partial Seizures" (M91-604 including administrative changes #1, 2, 3, and 4), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Ciba Geigy Corporation - "Safety and Efficacy of High versus Low Dose xxxxxxxxxxxx Monotherapy in Patients with Inadequately Controlled Partial Onset Seizures" (47680-02-028 including amendment #1), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Parke-Davis - "Xxxxxxxxxx Monotherapy Trial - A 4-Month, Double-Blind, Dose-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Gabapentin in Newly Diagnosed Patients with Partial Epilepsy" (945-213), July 1997 - 1998 (co-Principal Investigators: Dr. Ahmad Beydoun and Dr. Navin Varma)

CoCensys, Inc. - "A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of xxxxxxxxxxx in Patients Undergoing Evaluation to Determine Suitability for Surgical Treatment of complex Partial Seizures" (1042-0104.13 including amendment #1 and #2), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

Astra Merck, Inc. - "A Comparator Dose Controlled, Ascending Multiple Dose Safety and Tolerability Study of xxxxxxxxxxx Hydrochloride as an Adjunctive Therapy in Refractory Patients with Epilepsy" (134), July 1997 - 1998 (Principal Investigator: Dr. Ahmad Beydoun)

ICOS Corporation - "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of xxxxxxxxxxx in Patients with Acute Ischemic Stroke" (ASTO2 including amendment #1 and #2), July 1999-June 2000 (Principal Investigator: Dr. E. Eugene Marsh, sub-investigator Dr. James D. Geyer).

Glaxo Wellcome - "Patient Treatment Preference for and Satisfaction with Migraine Headache Therapy: xxxxxx Tablets Versus Current (non-triptan) Therapy." January 2000 - December 2000. (Principal Investigator: Dr. James D. Geyer).

Ortho-McNeil Pharmaceutical - "xxxxxxx: Action of Co-therapy on Tolerability in the Clinical Setting (TACTICS)". January 2000 (Principal Investigator: Dr. James D. Geyer).

Centocor - "xxxxxxx for Acute Ischemic Stroke: A Randomized, Double-blind, Placebo-controlled Trial." May 2000. (Principal Investigator: Dr. E. Eugene Marsh, Sub-investigator: Dr. James D. Geyer).

UCB Pharma -- "A Phase IV, Open-Label, Multi-Center Community-Based Trial Studying the Safety and Efficacy of xxxxxxxxxxxx as Add-on Therapy in Adult Patients with Treatment-Resistant, Partial-Onset Epilepsy. May 2000 (Principal Investigator: Dr. James D. Geyer).

Allergan, Inc. - "A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study of Pulmonary Function Safety of xxxxx Purified Neurotoxin Complex for the Treatment of Focal Spasticity Post-Stroke.

August 2000-April 2001. (Principal Investigator: Dr. James D. Geyer).

Parke-Davis – “XXXXXXXXXX BID Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study in Patients with Partial Seizures (Protocol 1008-145) October 2000-March 2001. (Principal Investigator: Dr. James D. Geyer).

Parke-Davis – “XXXXXXXXXX BID Open-Label Add-On Trial: A Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures (Protocol 1008-146) October 2000-March 2001. (Principal Investigator: Dr. James D. Geyer).

Sanofi-Synthelabo – Management of Atherothrombosis with XXXXXXXXXXXXX in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study with 18 Months of Follow-up, October 2001- present. (Principal Investigator: Dr. E. Eugene Marsh)

GlaxoSmithKline – “A Double-blind, Randomised, Placebo Controlled, Parallel Group to Investigate the Tolerability of a Dose Escalating Regimen of XXXXX in Patients Suffering from Restless Legs Syndrome (RLS),” December 2001-September 2002. (Principal Investigator: Dr. James D. Geyer)

Astra-Zeneca – “A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Early Efficacy and Tolerability of XXXXXXXXXXXXX in the Acute Treatment of Adult Subjects with Migraine. November 2002 – August 2003. (Principal Investigator – Dr. Daniel C. Potts)

Pfizer – “A 15 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of XXXXXXXXXXXXX for Efficacy and Quality of Life in Patients with Painful Diabetic Peripheral Neuropathy. January 2003 – present. (Principal Investigator: Dr. James Geyer)

GlaxoSmithKline – “A 52 Week Open-Label Extension Study of the Long Term Safety of XXXXXXXXXXXXX in Subjects Suffering From Restless Leg Syndrome (RLS). January 2003- present. (Principal Investigator: Dr. James D. Geyer)

Allergan – 191622-056-00: “A Multicenter, Open-Label Study of the Safety of Repeated Doses of XXXXXXX for the Treatment of Focal Upper Limb Poststroke Spasticity.”
April 2003 – present. (Principal Investigator Dr. James Geyer)

GlaxoSmithKline – “A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXXXX in Patients Suffering from Restless Legs Syndrome (RLS)”
January 2004 – present (Principal Investigator James Geyer, M.D.)

GlaxoSmithKline – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of XXXXXXXXXXXXX in Subjects with Neuropathic Pain and Inadequate Pain Relief with Gabapentin, Tricyclic Anti-depressants or Non-Narcotic Analgesics
February 2004 – present (Principal Investigator – James Geyer, M.D.)

Eli Lilly and Centocor – “ XXXXXXX in Acute Ischemic Stroke: A Phase III Multination, Multicenter, randomized, Double-Blind, Placebo-controlled Trial”
April 2004- present (Principal Investigator – E. Eugene Marsh, III.)